BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38387918)

  • 21. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
    Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
    Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of gene mutation characteristics and its correlation with prognosis in patients with myelodysplastic syndromes.
    Yang X; Zhao H; Wu H; Guo X; Jia H; Liu W; Wei Y; Can C; Ma D
    Clin Chim Acta; 2024 Feb; 554():117789. PubMed ID: 38246208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Analysis of mutations of 14 genes among 87 patients with myelodysplastic syndrome].
    Zhou X; Jin H; Mu Q; Sheng L; Lai B; Zhu H; Ouyang G
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Oct; 36(10):953-956. PubMed ID: 31598934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.
    Heuser M; Gabdoulline R; Löffeld P; Dobbernack V; Kreimeyer H; Pankratz M; Flintrop M; Liebich A; Klesse S; Panagiota V; Stadler M; Wichmann M; Shahswar R; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Geffers R; Schlegelberger B; Göhring G; Kreipe HH; Germing U; Ganser A; Kröger N; Koenecke C; Thol F
    Ann Hematol; 2017 Aug; 96(8):1361-1372. PubMed ID: 28612220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
    Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E
    Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes and characteristics of patients with
    Zhang L; Chen K; Li Y; Chen Q; Shi W; Ji T; Tao H; He Z; Wang C; Yu L
    Hematology; 2023 Dec; 28(1):2181773. PubMed ID: 36892252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center].
    Qu SQ; Pan LJ; Qin TJ; Xu ZF; Li B; Wang HJ; Sun Q; Jia YJ; Li CW; Cai WY; Gao QY; Jiao M; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):373-379. PubMed ID: 37550186
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.
    Hou HA; Kuo YY; Tang JL; Chou WC; Yao M; Lai YJ; Lin CC; Chen CY; Liu CY; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Feb; 89(2):181-6. PubMed ID: 24127063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
    Badar T; Vanegas YAM; Nanaa A; Foran JM; Al-Kali A; Mangaonkar A; Murthy H; Alkhateeb HB; Viswanatha D; He R; Shah M; Yi CA; Litzow MR; Gangat N; Tefferi A; Patnaik MM
    Blood Cancer J; 2023 Sep; 13(1):149. PubMed ID: 37735430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive analysis of genetic factors predicting overall survival in Myelodysplastic syndromes.
    Maurya N; Mohanty P; Dhangar S; Panchal P; Jijina F; Mathan SLP; Shanmukhaiah C; Madkaikar M; Vundinti BR
    Sci Rep; 2022 Apr; 12(1):5925. PubMed ID: 35396491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Genetics of Myelodysplastic Syndromes: Clinical Relevance.
    Chiereghin C; Travaglino E; Zampini M; Saba E; Saitta C; Riva E; Bersanelli M; Della Porta MG
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique.
    Owattanapanich W; Herzig J; Jahn N; Panina E; Ruchutrakool T; Kungwankiattichai S; Issaragrisil S; Döhner H; Döhner K
    Ann Hematol; 2021 Aug; 100(8):1983-1993. PubMed ID: 33839881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes.
    Xu F; Wu LY; He Q; Wu D; Zhang Z; Song LX; Zhao YS; Su JY; Zhou LY; Guo J; Chang CK; Li X
    Sci Rep; 2017 Feb; 7():43113. PubMed ID: 28220884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromes.
    Lee WH; Lin CC; Wang YH; Yao CY; Kuo YY; Tseng MH; Peng YL; Hsu CA; Sun HI; Chuang YK; Hsu CL; Tien FM; Tsai CH; Chou WC; Hou HA; Tien HF
    Hematol Oncol; 2023 Aug; 41(3):463-473. PubMed ID: 36420747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
    Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
    Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Risk factors for leukemia transformation in patients with myelodysplastic syndromes].
    Zhao SY; Xu ZF; Qin TJ; Qu SQ; Li CW; Jia YJ; Pan LJ; Li B; Gao QY; Jiao M; Huang HJ; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2022 Oct; 43(10):818-825. PubMed ID: 36709195
    [No Abstract]   [Full Text] [Related]  

  • 38. [Analysis of ASXL1 gene variant in patients with myelodysplastic syndrome].
    Chen M; Liu J; Chao H; Qin W; Jiang N; Lu X; Cen L; Jiang Y; Cai X; Zhang R; Wang Q
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Feb; 37(2):110-115. PubMed ID: 32034733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
    Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
    Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study.
    GenoMed4All consortium
    Lancet Haematol; 2023 Feb; 10(2):e117-e128. PubMed ID: 36436542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.